Drugs Made in America Acquisition Corp

Drugs Made In America Acquisition Corp, a Nasdaq‑listed SPAC, trades near $10.33 with a $347 million market cap and a 48‑P/E ratio—investors eye its upcoming merger plans and potential growth prospects.

Drugs Made In America Acquisition Corp. is actively seeking a pharmaceutical target to merge with or acquire, as part of its strategy to enhance its portfolio and market presence.